The patient, a 50-year-old woman (gravida 2, para 2), visited the local clinic for constipation. Image studies revealed a 10 cm, heterogenous, multi-septated mass in both ovaries. Initial CA 125 was 100.7 U/ml. A pap smear was performed, and the result was negative. During surgery, the tumor was noted to arise from both ovaries. Laparoscopic bilateral salpingo-oophorectomy was performed. Microscopic evaluation of the right ovary revealed ovarian choriocarcinoma, a borderline mucinous tumor, and metastatic adenocarcinoma. Left ovary evaluation revealed an ovarian borderline mucinous tumor and metastatic adenocarcinoma. After confirming the final histological examination, laparoscopic re-staging surgery was performed. Microscopic finding of the uterus was endocervical adenocarcinoma with direct extension to the endometrium and myometrium and a pelvic lymph node on the left side revealed metastatic adenocarcinoma. After surgery, we performed concurrent chemo-radiation therapy with weekly cisplatin (50 mg/m2) for cervical cancer. Abdominal CT was performed and there was no evidence of recurrence. However, -HCG increased from 18.6 to 65.24 (mIU/ml). Chemotherapy was decided and treatment with an EMA-CO regimen was started. At this time, a lesion was observed in the right upper lobe of the chest radiograph. Three cycles of EMA-CO chemotherapy were performed. -HCG after three cycles of chemotherapy was 93.64 (mIU/ml). On chest CT, the size of the nodule in the right upper lobe was increased to 2 cm. Therefore, We changed chemotherapy regimen into Paclitaxel andcarboplatin. AfCHter the second cycle of chemotherapy, the patient was admitted due to worsening of chest metastases with fever, sore throat, and leukopenia. Chest nodule was confirmed to chroicarcinoma through fine needle aspiration biopsy and serum level of -HCG was increased after changing the regimen with EP-EMA and topotecan and bevacizumab. She died after brain metastasis.